US FDA Advisory Committees Could Get Revamp With A Focus On Science Over Emotion
Executive Summary
CDER Director Cavazzoni also wants to loosen conflict of interest rules and improve technology for remote meetings. Given FDA’s approval of Aduhelm, her comments, made in a prerecorded interview for the BIO Digital annual meeting, may raise some eyebrows. Industry is also working on recommendations for the agency on the topic.
You may also be interested in...
Docket Open For OTC Oral Phenylephrine GRASE Meeting, And So Is NDAC Consumer Member Seat
Docket opened for 11-12 September NDAC meeting to consider oral phenylephrine GRASE data available since the agency last examined the ingredient. FDA also accepting nominations for individuals or representatives of consumer organizations for vacancies in voting or non-voting seats across its drug and medical technology advisory committees.
US FDA Looks To Assure Advisory Committees' Subject Expertise With More Temporary Members
Reform efforts in CDER include ensuring expertise is specific to the issues being discussed, which may mean more temporary voting members on advisory committees.
Expect More Temporary Members Voting In US FDA Advisory Committees
Reform efforts in CDER include ensuring expertise is specific to the issues being discussed, which may mean more temporary voting members on advisory committees.